Topic: Dexamethasone

Dr. Bartlett cites the STOIC trial from Oxford University, which found that inhaled budesonide could prevent 90% of COVID-related hospitalizations. He compares this to the use of dexamethasone in ICUs, noting that early intervention with an inexpensive, generic steroid is a more effective strategy. The medicine is described as safe and widely available in pharmacies.

Dr. Ardis claims that the addition of Dexamethasone and Vancomycin to hospital protocols has increased the rate of kidney failure, making the Delta variant appear more dangerous to young people. He argues that survival rates are higher for those who stay home and use early treatments. Ardis suggests that doctors in ICUs are becoming complicit in a protocol that has killed hundreds of thousands of Americans.

Scott Miller recounts a specific intervention in Portland where a patient was successfully treated with high-dose methylprednisolone and antibiotics for a secondary bacterial pneumonia. Despite the patient's rapid improvement, Miller claims the hospital refused to credit the alternative treatments and attempted to return the patient to standard dexamethasone protocols. The FLCCC Alliance is cited as a resource for these alternative treatment protocols.

Dr. Brian Artis warns that the hospital drug Remdesivir causes acute kidney failure in 31% of patients, leading to fluid in the lungs. Kate Daly notes that Fauci established Remdesivir as the "standard of care" despite its 56% mortality rate in previous Ebola trials. Artis claims that the combination of Remdesivir, dexamethasone, and vancomycin is lethal for many COVID-19 patients.